White Paper
Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning
Fears have arisen regarding a resurgence in COVID-19 cases. Numerous factors could be contributing to a resurgence in COVID-19 cases. Some suggest it is because more tests are bein ...
White Paper
Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?
Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...
White Paper
AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...
Report
Future Of Pharma: Evolving Commercial Models – Part 1
The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...
White Paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
White Paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White Paper
The Causes and Solutions of Chronic Drug Shortages in the United States
While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...
White Paper
Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary
No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...
White Paper
Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes
The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...
White Paper
The Reasons for and Solutions to Chronic Drug Shortages in the United States
This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...
White Paper
Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues
The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...
White Paper
Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?
The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...
White Paper
Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?
The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...
White Paper
The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment
The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...
